Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Total Inventories : $106.6 Mil (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co Total Inventories?

Biohaven Pharmaceutical Holding Co's total inventories for the quarter that ended in Jun. 2022 was $106.6 Mil. Biohaven Pharmaceutical Holding Co's average total inventories from the quarter that ended in Mar. 2022 to the quarter that ended in Jun. 2022 was $98.9 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Biohaven Pharmaceutical Holding Co's Net-Net Working Capital per share for the quarter that ended in Jun. 2022 was $-18.51.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biohaven Pharmaceutical Holding Co's Days Inventory for the three months ended in Jun. 2022 was 252.55.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biohaven Pharmaceutical Holding Co's Inventory Turnover for the quarter that ended in Jun. 2022 was 0.36.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue for the quarter that ended in Jun. 2022 was 0.46.

Biohaven Pharmaceutical Holding Co Total Inventories Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Total Inventories Chart

Biohaven Pharmaceutical Holding Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Inventories

Get a 7-Day Free Trial

39.56

80.61

Biohaven Pharmaceutical Holding Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Total Inventories	Get a 7-Day Free Trial															64.06	74.86	80.61	91.28	106.56

Biohaven Pharmaceutical Holding Co Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Biohaven Pharmaceutical Holding Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2022 is

	Net-Net Working Capital Per Share (Q: Jun. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(553.486	+	0.75 * 352.449	+	0.5 * 106.561	-	2191.807
-	0	-	-4.625)	/	71.1111
=	-18.51

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biohaven Pharmaceutical Holding Co's Days Inventory for the three months ended in Jun. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2022 )	/	Cost of Goods Sold (Q: Jun. 2022 )	*	Days in Period
	=	98.921	/	35.741	*	365 / 4
	=	252.55

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biohaven Pharmaceutical Holding Co's Inventory Turnover for the quarter that ended in Jun. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2022 )	/	Average Total Inventories (Q: Jun. 2022 )
	=	35.741	/	98.921
	=	0.36

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biohaven Pharmaceutical Holding Co's Inventory to Revenue for the quarter that ended in Jun. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2022 )	/	Revenue (Q: Jun. 2022 )
	=	98.921	/	215.079
	=	0.46

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Biohaven Pharmaceutical Holding Co Total Inventories Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Executives

Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock	officer: Chief Medical Officer	215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart	officer: Chief Financial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten	officer: Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director, 10 percent owner	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr	officer: CCO-Migraine & Common Disease	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile	officer: VP of Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman	officer: Chief Medical Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton	officer: Chief Commercial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054